Clinical Trial

Midline Versus Paramedian Approaches in Treating Degenerative Lumbar Spondylolisthesis

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 21, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
For the increasing numbers of patients undergoing fusion procedures for the degenerative lumbar spine, infection and re-operation can negatively impact outcomes. Numerous observational and retrospective reviews have shown advantages to para-median versus midline approaches; however, recent systematic reviews have shown a need for a well-powered, prospective randomized control trials comparing both exposures. As a step towards a long-term goal of an RCT to address this issue, the purpose of this pilot study is to gather initial data to examine whether operative approach impacts the short-term infection rate, re-operation rate, length of stay, and overall costs to the system. Patients deemed appropriate surgical candidates with single or two-level degenerative spondylolisthesis will be approached for participation, and randomized into either the midline or paramedian group. Initial follow-ups will be at 2 and 6 weeks, and 3 months. Infection rates, inpatient and outpatient adverse events, re-operation rates, radiation exposure and costs will be determined. Cost effectiveness analysis will be estimated comparing each procedure using a bottom-up estimation. Post-operative wound infection can have a significant effect on patient short and long term outcomes. If a significant difference in infection rate is demonstrated, as well as lower re-operation rates, shorter stays, and decreased overall costs, adoption of paramedian approaches to single or two-level fusions of the lumbar spine might be suggested, providing fuel for a full-scale RCT.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2017-11-15.
Status change: Not Yet Recruiting → Recruiting 2024-08-19
Trial Details
NCT Number NCT03344484
Lead Sponsor Nova Scotia Health Authority
Conditions Spondylolisthesis, Lumbar Region
Enrollment 100 participants
Start Date 2018-01-30
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-08-21